Results 31 to 40 of about 9,514 (200)
Differential Histone Posttranslational Modifications Induced by DNA Hypomethylating Agents
Cancer Control, 2022 Introduction The prototype DNA hypomethylating agents 5-azacytidine (5AC) and decitabine (DAC) are currently FDA-approved for treatment of blood and bone marrow disorders like myelodysplastic syndrome.
Sridhar A Malkaram +7 more
doaj +1 more source
PANoptosis in the pathogenesis of myelodysplastic syndromes
Molecular Oncology, EarlyView.PANoptosis, a combination of three types of programmed cell death, is mediated by a large protein complex called a PANoptosome. In healthy bone marrow hematopoietic cells, PANoptosis is restricted by inhibitory signaling. In MDS, bone marrow cells become sensitive to the PANoptotic stimuli due to the aberrant inactivation of inhibitory signaling or ...
Rohit Thalla +4 more
wiley +1 more source
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
Mediterranean Journal of Hematology and Infectious Diseases, 2013 Patients with ≥ 20% 30% BM blast AML. In the present review, we will discuss the clinical results achieved in the treatment of elderly patients with 20%-30% BM blasts AML using intensive chemotherapy (IC) or hypomethylating agents.
Luca Maurillo +12 more
doaj +1 more source
Xenogeneic Mitochondrial Transplantation Improves Selected Age‐Associated Phenotypes in Mice
Advanced Science, EarlyView.Yak‐derived xenogeneic mitochondrial transplantation improves selected age‐associated phenotypes in mice, enhances mitochondrial functional readouts, and engages host mitochondrial quality‐control pathways. Broad tissue biodistribution, increased ATP production and mtDNA copy number, reduced ROS levels and dysfunctional mitochondria, improved motility ...
Wenpeng Li +5 more
wiley +1 more source
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
Mediterranean Journal of Hematology and Infectious Diseases, 2017 In 2002, the WHO classification reduced the proportion of blasts in the bone marrow (BM) necessary for the diagnosis of acute myeloid leukemia (AML) from 30% to 20%, eliminating the RAEB-t subtype of myelodysplastic syndromes (MDS).
Eleonora De Bellis +11 more
doaj +1 more source
Advanced Science, EarlyView.NSUN2‐mediated m5C modification cooperates with ALYREF to stabilize and export IP3R3 mRNA, increasing IP3R3 expression and Ca2 + overload in chondrocytes. This signaling promotes mitochondrial dysfunction, NLRP3 inflammasome activation, and senescence, thereby accelerating osteoarthritis progression.
Guping Mao +8 more
wiley +1 more source
A critical role of epigenetic inactivation of miR-9 in EVI1high pediatric AML
Molecular Cancer, 2019 Ectopic Viral Integration site 1 (EVI1) upregulation is implicated in 10–25% of pediatric acute myeloid leukemia (AML) and has an inferior outcome with current chemotherapy regimens. Here we report that EVI1 upregulation is associated with methylation of
Nupur Mittal +7 more
doaj +1 more source
Low-intensity regimens standard-intensity induction strategies in acute myeloid leukemia
Therapeutic Advances in Hematology, 2020 Treatment options for elderly patients with acute myeloid leukemia (AML) remain limited. In this age group, AML is frequently associated with poor-risk features, while patients’ present comorbidities and reduced functional reserves.
Norbert Vey
doaj +1 more source
Advanced Science, EarlyView.A novel epitranscriptomic mechanism in rheumatoid arthritis is uncovered: NSUN2 promotes disease via m5C‐dependent stabilization of ICMT mRNA, fueling the migration and invasion of pathogenic RA FLS. Targeting this axis with engineered nanoparticles (Ce/SAA NPs) effectively inhibits disease progression, presenting a precise therapeutic strategy ...
Ruiru Li +15 more
wiley +1 more source
Clinical and Translational Science, 2021 Reduced expression of the uptake transporter, OCTN1 (SLC22A4), has been reported as a strong predictor of poor event‐free and overall survival in multiple cohorts of patients with acute myeloid leukemia (AML) receiving the cytidine nucleoside analog ...
Daelynn R. Buelow +9 more
doaj +1 more source